JP2022537555A - ウイルスベースの遺伝子療法による治療方法 - Google Patents
ウイルスベースの遺伝子療法による治療方法 Download PDFInfo
- Publication number
- JP2022537555A JP2022537555A JP2021575397A JP2021575397A JP2022537555A JP 2022537555 A JP2022537555 A JP 2022537555A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2022537555 A JP2022537555 A JP 2022537555A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- gene therapy
- viral
- smrt
- ncor2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864404P | 2019-06-20 | 2019-06-20 | |
| US62/864,404 | 2019-06-20 | ||
| US201962867172P | 2019-06-26 | 2019-06-26 | |
| US62/867,172 | 2019-06-26 | ||
| PCT/US2020/038643 WO2020257586A2 (en) | 2019-06-20 | 2020-06-19 | Method of treatment with viral-based gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537555A true JP2022537555A (ja) | 2022-08-26 |
| JP2022537555A5 JP2022537555A5 (cg-RX-API-DMAC7.html) | 2023-06-23 |
Family
ID=71579659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575397A Pending JP2022537555A (ja) | 2019-06-20 | 2020-06-19 | ウイルスベースの遺伝子療法による治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200405883A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986481A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022537555A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114375205A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020257586A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114277057B (zh) * | 2021-07-09 | 2023-10-13 | 上海天泽云泰生物医药有限公司 | 用于治疗或预防b型血友病的重组腺相关病毒载体和方法 |
| CN115772214B (zh) * | 2022-11-30 | 2023-09-29 | 湖南家辉生物技术有限公司 | F8突变体蛋白、f8基因突变体、检测f8基因突变体的引物组合、试剂及应用 |
| TW202444398A (zh) * | 2023-01-09 | 2024-11-16 | 美商拜奧馬林製藥公司 | 表觀遺傳修飾劑改善aav基因療法之耐久性 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017531652A (ja) * | 2014-10-06 | 2017-10-26 | アルスロジェン ビー.ブイ.Arthrogen B.V. | Aavに基づく遺伝子治療 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| US20020014242A1 (en) * | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| BRPI0214168B8 (pt) | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| CN101346395A (zh) | 2005-12-30 | 2009-01-14 | 默克专利有限公司 | 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| WO2008019061A2 (en) | 2006-08-03 | 2008-02-14 | Vaccinex, Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
| WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
| JP2011520898A (ja) | 2008-05-13 | 2011-07-21 | ノビミューン エスアー | 抗il−6/il−6r抗体およびそれらの使用方法 |
| MX2011000071A (es) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| KR20110094307A (ko) | 2008-11-13 | 2011-08-23 | 펨타 파마슈티컬스, 인크. | 인간화된 항-il-6 항체 |
| WO2010115995A2 (en) | 2009-04-10 | 2010-10-14 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| US20110059080A1 (en) | 2009-09-08 | 2011-03-10 | Mark Cornfeld | Use of an anti-il6 antibody to decrease hepcidin in cancer patients |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| CN115094062A (zh) * | 2015-04-16 | 2022-09-23 | 埃默里大学 | 用于肝脏中蛋白质表达的重组启动子和载体及其用途 |
| AU2016302768B2 (en) * | 2015-07-31 | 2019-08-22 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| JP2018535929A (ja) * | 2015-09-24 | 2018-12-06 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| BR112018008900A8 (pt) | 2015-11-03 | 2019-02-26 | Regeneron Pharma | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas |
| CN108884145B (zh) * | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
| KR102404550B1 (ko) * | 2015-11-13 | 2022-05-31 | 다케다 야쿠힌 고교 가부시키가이샤 | A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터 |
| WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| JP2020506890A (ja) * | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与 |
| JP7630906B2 (ja) * | 2017-02-01 | 2025-02-18 | イェール・ユニヴァーシティー | 利尿薬耐性の治療 |
| WO2018200951A1 (en) * | 2017-04-28 | 2018-11-01 | Tran David T | Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions |
| TWI753168B (zh) | 2017-05-22 | 2022-01-21 | 日商武田藥品工業股份有限公司 | 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體 |
| CN111051343B (zh) | 2017-09-13 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Il-6r抗体、其抗原结合片段及医药用途 |
| CN109867723B (zh) | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
-
2020
- 2020-06-19 CN CN202080044892.9A patent/CN114375205A/zh active Pending
- 2020-06-19 WO PCT/US2020/038643 patent/WO2020257586A2/en not_active Ceased
- 2020-06-19 US US16/906,349 patent/US20200405883A1/en not_active Abandoned
- 2020-06-19 JP JP2021575397A patent/JP2022537555A/ja active Pending
- 2020-06-19 EP EP20739798.5A patent/EP3986481A2/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017531652A (ja) * | 2014-10-06 | 2017-10-26 | アルスロジェン ビー.ブイ.Arthrogen B.V. | Aavに基づく遺伝子治療 |
Non-Patent Citations (2)
| Title |
|---|
| KLAUDIA KURANDA ET AL.: ""Exposure to wild-type AAV drives distinct capsid immunity profiles in humans"", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, JPN6024027726, 22 October 2018 (2018-10-22), pages 5267 - 5279, ISSN: 0005613709 * |
| VICTORIA M. VELAZQUEZ ET AL.: ""Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting"", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 4, JPN6024027727, March 2017 (2017-03-01), pages 159 - 168, ISSN: 0005613710 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986481A2 (en) | 2022-04-27 |
| CN114375205A (zh) | 2022-04-19 |
| WO2020257586A3 (en) | 2021-03-04 |
| US20200405883A1 (en) | 2020-12-31 |
| WO2020257586A2 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herzog et al. | Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | |
| JP6462044B2 (ja) | 第viii因子療法を受けている個体における第viii因子に対する免疫原性を低下させる方法 | |
| KR102766526B1 (ko) | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 | |
| Vercelli et al. | Regulation of IgE synthesis in humans: a tale of two signals | |
| JP6831779B2 (ja) | 修飾された第ix因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用 | |
| JP6290270B2 (ja) | 遺伝子操作した樹状細胞および癌の治療のための使用 | |
| US20210261919A1 (en) | Methods and compositions for treating cancer | |
| AU2019392915B2 (en) | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases | |
| AU2017214378A1 (en) | Optimized Factor VIII genes | |
| US20200405883A1 (en) | Method of treatment with viral-based gene therapy | |
| US20240117364A1 (en) | Synthetic immunomodulation with a crispr super-repressor in vivo | |
| US20230133243A1 (en) | Conditioning regimens for in vivo gene therapy | |
| US20250242056A1 (en) | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing | |
| US20230159649A1 (en) | Methods and combinations for dual targeting of tnf family members | |
| Nayak et al. | Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B | |
| CN119095612A (zh) | 用于在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒 | |
| TW202006141A (zh) | 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法 | |
| US8063022B1 (en) | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy | |
| US20240269241A1 (en) | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression | |
| RU2799048C2 (ru) | Улучшение клинических параметров посредством экспрессии фактора viii | |
| Byrne | The Generation and Characterisation of Novel Mouse Models of Haemophilia A | |
| JP2003146909A (ja) | 治療用ポリペプチドに対する免疫寛容の誘導 | |
| WO2024238591A2 (en) | Methods of treating anti-aav seropositive hemophilia patients | |
| HK40121378A (en) | Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy | |
| TW202546235A (zh) | 腺相關病毒載體序列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230615 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240716 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250610 |